This patient is enrolled in the HGB-205 Study being conducted in Paris, France. bluebird has also opened a separate US-based trial in the United States for the treatment of up to 8 severe sickle cell disease patients with the company's LentiGlobin BB305 drug product.
http://ift.tt/11jnd58
http://ift.tt/11jnd58
No comments:
Post a Comment